A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies

Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab–imdevimab, and bamlanivimab have provided valuable options for the treat...

Full description

Saved in:
Bibliographic Details
Published inCurrent oncology (Toronto) Vol. 29; no. 6; pp. 3940 - 3949
Main Authors Owen, Carolyn, Robinson, Sue, Christofides, Anna, Sehn, Laurie H.
Format Journal Article
LanguageEnglish
Published MDPI 31.05.2022
MDPI AG
Subjects
coronavirus
COVID-19
hematology
malignancy
Review
Online AccessGet full text

Cover

More Information
Summary:Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab–imdevimab, and bamlanivimab have provided valuable options for the treatment of COVID-19 disease. More recently, monoclonal antibodies have been examined for the prevention of COVID-19 infection. The monoclonal antibody combination, tixagevimab–cilgavimab, was recently approved by Health Canada as pre-exposure prophylaxis against COVID-19 in individuals who are immunocompromised or where vaccination is not recommended. Prophylactic approaches such as the use of tixagevimab–cilgavimab, in addition to COVID-19 vaccination, may provide additional protection for patients with hematological malignancies who are at greater risk of serious outcomes from COVID-19 infection.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol29060315